2

2.0%) (Calverley em et al /em ., 2010a). therefore represents a significant addition to current restorative choices for COPD individuals with chronic bronchitis, including those that stay symptomatic despite treatment. This informative article reviews the existing position of PDE4 inhibitors, concentrating on the pharmacokinetics, protection and effectiveness of roflumilast. In particular, it provides a synopsis of the consequences of roflumilast on lung exacerbations and function, blood sugar homoeostasis and pounds loss, as well as the concomitant usage of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists. LINKED Content articles This article can be section of a themed concern on Respiratory Pharmacology. To see the other content articles in this problem check out http://dx.doi.org/10.1111/bph.2011.163.issue-1 and = 1411Post-bronchodilator FEV1 30C80% predicted; post-bronchodilator FEV1:FVC percentage 70%Multicentre, NMS-P515 double-blind, parallel-group studyRoflumilast 250 g (= 576) or 500 g (= 555) or placebo (= 280) once daily for 24 weeksRoflumilast 500 g considerably improved post-bronchodilator FEV1 weighed against placebo (difference 97 mL, 0.0001) and health-related quality of lifeM2-111(Data on document Nycomed GmbH) (Nycomed GmbH, 2010a)= 1176Post-bronchodilator FEV1:FVC percentage 70%Post-bronchodilator 50% predictedMulticentre, double-blind, parallel-group studyRoflumilast 500 g (= 568) or placebo (= 608) once daily for 52 weeksRoflumilast 500 g significantly improved pre-bronchodilator FEV1 weighed against placebo (difference 36 mL, 0.0001)Roflumilast 500 g significantly improved post-bronchodilator FEV1 weighed against placebo (difference 38 mL, NUFIP1 0.0001)M2-112 (Calverley = 1513Post-bronchodilator FEV1 50% predicted, post-bronchodilator FEV1:FVC percentage 0.70Multicentre, randomized, placebo-controlled, double-blind, parallel-group trial (identical to review M2-111)Roflumilast, 500 g once daily or placebo for 1 yearNote: unlike M2-124/125, individuals with this study weren’t required to possess symptoms of chronic bronchitis or a brief history of exacerbationsPost-bronchodilator FEV1 increased by 39 mL with roflumilast weighed against placebo by 52 weeks (= 0.001)The mean exacerbation price per patient each year was low and similar (0.86 vs 0.92 for roflumilast and placebo respectively). Inside a retrospective evaluation, the exacerbation price per patient each year in individuals in Yellow metal stage IV disease was 36% reduced individuals treated with roflumilast than in those treated with placebo (1.01 vs. 1.59, respectively; = 0.024)M2-124 (Calverley = 1523Post-bronchodilator FEV1 50% predicted, bronchitic symptoms, and a history background of exacerbationsMulticentre, double-blind, randomized, parallel-group studyRoflumilast 500 g (= 765) once daily or placebo (= 758) for 1 yearPre-bronchodilator FEV1 increased in the roflumilast group by 46 mL, but was almost unchanged (8 mL boost) in the placebo group (= 0.0003)There is also 14.9% decrease in the exacerbation rate in the roflumilast group vs placebo NMS-P515 (= 0.0278)M2-125 (Calverley = 1568Post-bronchodilator FEV1 50% predicted, bronchitic symptoms, and a brief history of exacerbationsMulticentre, double-blind, randomized, parallel-group studyRoflumilast 500 g once daily (= 772) or placebo (= 796) for 1 yearRoflumilast increased pre-bronchodilator FEV1 by 33 mL weighed against a 25 mL reduction in the placebo group ( 0.0001)Roflumilast also reduced the price of serious or average COPD exacerbations compared with placebo by 18.5%; = 0.0035M2-127 (Fabbri = 933Post-bronchodilator FEV1 40C70% predictedDouble-blind, randomized, parallel-group, multicentre studyRoflumilast NMS-P515 500 g (= 466) or placebo (= 467), once for 24 weeks daily, furthermore to salmeterol 50 g dailyCompared with placebo, roflumilast improved mean pre-bronchodilator FEV1 by 49 mL ( 0 consistently.0001) in sufferers treated with salmeterol. Very similar improvement in post-bronchodilator FEV1 was observed. Furthermore, roflumilast acquired beneficial results on various other lung function measurements and on chosen patient-reported outcomesM2-128 (Fabbri = 743Post-bronchodilator FEV1 40C70% predictedDouble-blind, randomized, parallel-group, multicentre studyRoflumilast 500 g (= 371) or placebo (= 372).